▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #2848 by analyst upside · 2026-08-13
MCK
McKesson Corporation
Healthcare · Market Cap $102B · P/E 24.2x
ANALYST PRICE TARGET
+12.8%
implied upside to consensus target
Current Price $878.73
Consensus Target $991.4
Bull Target $1080.0
Bear Target $905.0
Analysts Covering 15
ANALYST CONSENSUS - BUY
Strong Buy
3
Buy
10
Hold
3
Sell
0
52-Week Low $661.69
52-Week High $999.0
YTD Return +6.9%
FUNDAMENTALS
Market Cap $102B
P/E Ratio (TTM) 24.2x
Forward P/E 17.4x
EPS (TTM) $36.29
PEG Ratio 1.66
Dividend Yield 0.42%
Revenue (TTM) $411.0B
Profit Margin 1.1%
52-WEEK RANGE
52-Week Low $661.69
52-Week High $999.0
Current Price $878.73
Bear Target $905.0
Bull Target $1080.0
● Now $878.73 ● Target $991.4
TRADING DATA
Avg Volume 1.1M
YTD Return +6.9%
Analyst Count 15
Consensus Buy
Upside to Target +12.8%
Last Updated 2026-08-13

ANALYST SUMMARY

McKesson Corporation (MCK) is currently trading at $878.73 with a Wall Street consensus price target of $991.4, implying potential upside of 12.8% over the next 12 months. 15 analysts currently cover MCK, with a consensus rating of Buy - 81% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $1080.0, while the most cautious has a target of $905.0.

MCK operates in the Healthcare sector with a market capitalisation of $102B. The stock is up 6.9% year-to-date and is currently trading near the upper end of its 52-week range of $661.69 – $999.0.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

ELV +12.5%
Elevance Health, Inc.
$87B · P/E 17.3x · Buy
HCA +9.6%
HCA Healthcare, Inc.
$90B · P/E 13.8x · Buy
REGN +4.5%
Regeneron Pharmaceuticals, Inc.
$82B · P/E 19.7x · Buy
VRTX +7.1%
Vertex Pharmaceuticals Incorporated
$133B · P/E 30.6x · Buy
SYK +10.0%
Stryker Corporation
$133B · P/E 36.0x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for MCK, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Barclays - Reiterated
Overweight → Overweight 2026-06-10 Building track record
Citigroup - Reiterated
Buy → Buy 2026-05-14 Building track record
Wells Fargo - Reiterated
Equal-Weight → Equal-Weight 2026-05-12 Building track record
UBS - Reiterated
Buy → Buy 2026-05-08 33% win rate (6 calls)
JP Morgan - Reiterated
Overweight → Overweight 2026-05-08 43% win rate (7 calls)
Evercore ISI Group - Reiterated
Outperform → Outperform 2026-05-08 Building track record
William Blair ● Initiated
Outperform 2026-04-28 44% win rate (9 calls)
UBS - Reiterated
Buy → Buy 2026-04-22 33% win rate (6 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
69
out of 100
Coverage depth
21/30
Consensus clarity
26/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →